Trials that use: P-values
New to this method? Read the tutorial →
10,201 results
- CapAppIndependent statistical analysis of Capillary Refill Time Measurement Utilizing Mobile Application in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05472116).
- CAPEIndependent statistical analysis of Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05512962).
- Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00565370).
- Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00347438).
- Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: primary endpoint results, effect estimate with confidence…
- Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CAPICAIndependent statistical analysis of Chlorhexidine-Alcohol Versus Povidone-Iodine for Cesarean Antisepsis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02202577).
- CAPITALCHILLIndependent statistical analysis of Mild Versus Moderate Therapeutic Hypothermia in Out-of-hospital Cardiac Arrest Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02011568).
- Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CAPPSIndependent statistical analysis of Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00135707).
- CAPSYSIndependent statistical analysis of Computer-Aided Prevention System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02444715).
- CAPTIVATEIndependent statistical analysis of CAPTIVATE (NCT02910583), a randomized phase 2 trial of ibrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia and small lymphocytic lymphoma, including its primary endpoints, statistical methods, and interpretation.
- CAPTUREIndependent statistical analysis of The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CAPYBARAIndependent statistical analysis of A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- CARAVAGGIOIndependent statistical analysis of Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00514540).
- Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM): Complete Statistical AnalysisIndependent statistical analysis of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CARDIndependent statistical analysis of Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Cardiac Rehabilitation Peer Mentorship: Complete Statistical AnalysisIndependent statistical analysis of Cardiac Rehabilitation Peer Mentorship: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02204449).
- Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment: Complete Statistical AnalysisIndependent statistical analysis of Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00447694).
- Cardio-pulmonary Rehabilitation and Sleep Quality: Complete Statistical AnalysisIndependent statistical analysis of Cardio-pulmonary Rehabilitation and Sleep Quality: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04668599).
- Cardiometabolic Effects of Pecans as a Snack: Complete Statistical AnalysisIndependent statistical analysis of Cardiometabolic Effects of Pecans as a Snack: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05071807).
- CARDIOSA-12Independent statistical analysis of Hypoglossal Nerve Stimulation on Cardiovascular Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03359096).
- Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03955952).
- Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults: Complete Statistical AnalysisIndependent statistical analysis of Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors – Effect of Fenofibrate: Complete Statistical AnalysisIndependent statistical analysis of Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CARDSIndependent statistical analysis of Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04427280).
- Care Partner Assisted Intervention to Improve Oral Health of Individuals With Mild Dementia: Complete Statistical AnalysisIndependent statistical analysis of Care Partner Assisted Intervention to Improve Oral Health of Individuals With Mild Dementia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CARE-ACTIndependent statistical analysis of Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CareConekta: A Smartphone App to Improve Engagement in HIV Care: Complete Statistical AnalysisIndependent statistical analysis of CareConekta: A Smartphone App to Improve Engagement in HIV Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03836625).
- Caregiver SOSIndependent statistical analysis of Caregiver Self-Management of Stress: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04337021).
- CARESIndependent statistical analysis of Community Collaboration to Advance Racial/Ethnic Equity in CRC Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05714644).
- CARES: A Mobile Health Program for Alcohol Risk Reduction: Complete Statistical AnalysisIndependent statistical analysis of CARES: A Mobile Health Program for Alcohol Risk Reduction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03927482).
- Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Caring for Babies During the Newborn Screening Blood Test: Complete Statistical AnalysisIndependent statistical analysis of Caring for Babies During the Newborn Screening Blood Test: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02608892).
- Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network: Complete Statistical AnalysisIndependent statistical analysis of Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CARTERIndependent statistical analysis of Circuitry Assessment and Reinforcement Training Effects on Recovery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04290988).
- Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects: Complete Statistical AnalysisIndependent statistical analysis of Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00834795).
- Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02717507).
- CARVIVA-HFIndependent statistical analysis of Heart Rate Reduction in Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01178528).